About
Ai Therapeutics develops inhaled therapeutics targeting pulmonary diseases driven by mTOR dysregulation, such as pulmonary hypertension and bronchiolitis obliterans syndrome, to modify disease progression.
Explore Ai Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.